Arena (ARNA) Short Interest Still High into Q4 Results
- Japan's Nikkei posts biggest point gain for fiscal year
- Citi downgrades tech stocks as its flagship indicator signals 'euphoria' levels
- UBS sees 5 warnings signals on semiconductor chip stocks
- 2 reasons why Tesla stock fell on Thursday
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- AMC Entertainment (AMC) Enters $250M ATM Agreement
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Home Depot (HD) to Acquire SRS Distribution for $18.25B EV
Arena (ARNA), VIVUS (VVUS) Face Uphill Obesity Battle as Costs Play Key Role
March 21, 2013 6:57 AM EDTArena Pharma (Nasdaq: ARNA) and VIVUS (Nasdaq: VVUS) are fighting the good fight. For profits.
Since the two received FDA approval for their respective obesity pills, Belviq and Qsymia, respectively, the drugs have yet to catch on with patients. Qsymia prescriptions are down 22 percent from a top hit on February 8th, which Belviq is yet to go on sale in the... More